Oncolytic Viruses in the Treatment of Bladder Cancer
Bladder carcinoma is the second most common malignancy of the urinary tract. Up to 85% of patients with bladder cancer are diagnosed with a tumor that is limited to the bladder mucosa (Ta, T1, and CIS). These stages are commonly termed as non-muscle-invasive bladder cancer (NMIBC). Although the trea...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Urology |
| Online Access: | http://dx.doi.org/10.1155/2012/404581 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850231584169394176 |
|---|---|
| author | Kyle G. Potts Mary M. Hitt Ronald B. Moore |
| author_facet | Kyle G. Potts Mary M. Hitt Ronald B. Moore |
| author_sort | Kyle G. Potts |
| collection | DOAJ |
| description | Bladder carcinoma is the second most common malignancy of the urinary tract. Up to 85% of patients with bladder cancer are diagnosed with a tumor that is limited to the bladder mucosa (Ta, T1, and CIS). These stages are commonly termed as non-muscle-invasive bladder cancer (NMIBC). Although the treatment of NMIBC has greatly improved in recent years, there is a need for additional therapies when patients fail bacillus Calmette-Guérin (BCG) and chemotherapeutic agents. We propose that bladder cancer may be an ideal target for oncolytic viruses engineered to selectively replicate in and lyse tumor cells leaving normal cells unharmed. In support of this hypothesis, here we review current treatment strategies for bladder cancer and their shortcomings, as well as recent advancements in oncolytic viral therapy demonstrating encouraging safety profiles and antitumor activity. |
| format | Article |
| id | doaj-art-0b7e6fac95b64dba939e0003d3b13c0c |
| institution | OA Journals |
| issn | 1687-6369 1687-6377 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Urology |
| spelling | doaj-art-0b7e6fac95b64dba939e0003d3b13c0c2025-08-20T02:03:28ZengWileyAdvances in Urology1687-63691687-63772012-01-01201210.1155/2012/404581404581Oncolytic Viruses in the Treatment of Bladder CancerKyle G. Potts0Mary M. Hitt1Ronald B. Moore2Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, T6G 2E1, CanadaDepartment of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, T6G 2E1, CanadaDepartment of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, T6G 2E1, CanadaBladder carcinoma is the second most common malignancy of the urinary tract. Up to 85% of patients with bladder cancer are diagnosed with a tumor that is limited to the bladder mucosa (Ta, T1, and CIS). These stages are commonly termed as non-muscle-invasive bladder cancer (NMIBC). Although the treatment of NMIBC has greatly improved in recent years, there is a need for additional therapies when patients fail bacillus Calmette-Guérin (BCG) and chemotherapeutic agents. We propose that bladder cancer may be an ideal target for oncolytic viruses engineered to selectively replicate in and lyse tumor cells leaving normal cells unharmed. In support of this hypothesis, here we review current treatment strategies for bladder cancer and their shortcomings, as well as recent advancements in oncolytic viral therapy demonstrating encouraging safety profiles and antitumor activity.http://dx.doi.org/10.1155/2012/404581 |
| spellingShingle | Kyle G. Potts Mary M. Hitt Ronald B. Moore Oncolytic Viruses in the Treatment of Bladder Cancer Advances in Urology |
| title | Oncolytic Viruses in the Treatment of Bladder Cancer |
| title_full | Oncolytic Viruses in the Treatment of Bladder Cancer |
| title_fullStr | Oncolytic Viruses in the Treatment of Bladder Cancer |
| title_full_unstemmed | Oncolytic Viruses in the Treatment of Bladder Cancer |
| title_short | Oncolytic Viruses in the Treatment of Bladder Cancer |
| title_sort | oncolytic viruses in the treatment of bladder cancer |
| url | http://dx.doi.org/10.1155/2012/404581 |
| work_keys_str_mv | AT kylegpotts oncolyticvirusesinthetreatmentofbladdercancer AT marymhitt oncolyticvirusesinthetreatmentofbladdercancer AT ronaldbmoore oncolyticvirusesinthetreatmentofbladdercancer |